Westside Investment Management Inc. Cuts Stock Position in Pulse Biosciences, Inc. (NASDAQ:PLSE)

Westside Investment Management Inc. lessened its holdings in Pulse Biosciences, Inc. (NASDAQ:PLSE) by 5.9% in the first quarter, according to its most recent filing with the SEC. The institutional investor owned 32,160 shares of the company’s stock after selling 2,015 shares during the period. Westside Investment Management Inc. owned 0.06% of Pulse Biosciences worth $280,000 as of its most recent SEC filing.

Separately, Griffin Asset Management Inc. boosted its holdings in shares of Pulse Biosciences by 15.7% during the 1st quarter. Griffin Asset Management Inc. now owns 300,320 shares of the company’s stock valued at $2,616,000 after purchasing an additional 40,700 shares during the last quarter. 76.95% of the stock is owned by institutional investors.

Pulse Biosciences Price Performance

PLSE opened at $11.54 on Thursday. The firm has a 50-day simple moving average of $10.32 and a two-hundred day simple moving average of $9.58. Pulse Biosciences, Inc. has a 52 week low of $3.78 and a 52 week high of $14.96.

Pulse Biosciences (NASDAQ:PLSE) last released its quarterly earnings data on Tuesday, May 7th. The company reported ($0.17) EPS for the quarter.

Analyst Upgrades and Downgrades

Separately, StockNews.com raised shares of Pulse Biosciences to a “sell” rating in a report on Thursday, June 27th.

Insiders Place Their Bets

In other news, CEO Burke Thomas Barrett acquired 10,000 shares of the firm’s stock in a transaction on Monday, May 20th. The stock was acquired at an average price of $8.56 per share, with a total value of $85,600.00. Following the completion of the purchase, the chief executive officer now directly owns 10,000 shares in the company, valued at $85,600. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 71.50% of the stock is owned by insiders.

Pulse Biosciences Company Profile

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. The company offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.